It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.11.28.23299155;](https://doi.org/10.1101/2023.11.28.23299155) this version posted December 1, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.11.28.23299155;](https://doi.org/10.1101/2023.11.28.23299155) this version posted December 1, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

demonstrated substantial effectiveness; for instance, letrozole has been shown to offer superior quality-adjusted survival rates compared to tamoxifen in a large-scale study involving over 900 patients with metastatic breast cancer [5]. The inclusion of these drugs in this integrative review reflects their widespread use and proven effectiveness in managing breast cancer.

The PharmGKB database serves as an extensive resource that compiles and curates knowledge on the impact of genetic variations on drug responses. This database gathers, curates, and disseminates information on clinically relevant gene-drug interactions and genotype-phenotype correlations [2, 3]. The application of PharmGKB in this integrative review provides a robust basis for examining how pharmacogenetics is being integrated into the personalization of first-line therapies for breast cancer.

This review endeavors to contribute to the scientific community by offering an analysis of how pharmacogenetics can be utilized to predict patient responses to first-line medications in breast cancer therapy, taking into account genetic variations and their effects on drug metabolism and efficacy. A more comprehensive understanding of these mechanisms can lead to the development of more effective and personalized treatment strategies for breast cancer.

METHODOLOGY

This study was formulated to answer the question: "How is pharmacogenomics applied to personalize first-line therapies in breast cancer treatment?" We undertook an integrative review of the PharmGKB, an international pharmacogenetics database, focusing on five primary breast cancer drugs: Letrozole, Anastrozole, Tamoxifen, Trastuzumab, and Pertuzumab. These drugs were selected based on their widespread use and demonstrated effectiveness in breast cancer therapy. Each plays a vital role in treatment, and their therapeutic responses may be affected by genetic variances. For each medication, we gathered all relevant "Clinical Annotations," particularly focusing on the gene, the variant, and the characteristics of carriers of each allele. We then collected "Variant Annotations" for all variants referenced in the clinical citations. Clinical annotations without corresponding variant information were excluded. The evidence level for each variant's data and the demographic origin of each study were also reviewed.

Through this methodology, we identified 68 clinical annotations related to key first-line drugs for breast cancer in the PharmGKB database. Pertuzumab, a monoclonal antibody used in HER2-Positive breast cancer, was the only drug without clinical data in the database. For each clinical annotation, we verified the presence of "variant annotations," which detail the genomic location of the variant, how it alters the genetic sequence, and its potential impact on 84 gene function. Nine clinical annotations lacking such details were omitted. Additionally, 3 clinical annotations were removed due to data redundancy, resulting in a total of 12 clinical annotations being excluded and 56 deemed eligible in the selection and eligibility phase. During the inclusion phase, each eligible clinical annotation was rigorously analyzed to rule

out data without sufficient statistical support or consideration of ethnic genetic differences.

Consequently, 44 clinical annotations were further excluded, leaving 12 for inclusion in this

review. Notably, none of the studies involving Trastuzumab met our criteria, as illustrated in:

Figure 1. Flowchart of Study Search and Selection.

105

For Letrozole, genotypes in various genes such as CYP19A1, CYP2A6, ESR1, and ESR2 have been identified as influencing the risk of bone density loss and the drug's metabolization rate. This information is crucial for dose adjustment and predicting treatment response in breast cancer patients.

110

111 In the case of Anastrozole, the UGT1A4 rs3732218 genetic variant has been shown to affect 112 the drug's glucuronidation. This indicates variability in the drug's elimination from the body, 113 which can influence both its efficacy and the incidence of side effects.

114

Regarding Tamoxifen, variations in the CYP2D6, ABCC2, ESR1, ESR2 genes, and a non-coding region have been demonstrated to significantly impact cancer recurrence, bone fracture risks, and alterations in cholesterol and triglyceride levels. These findings underscore the importance of considering the genetic profile in the selection and monitoring of Tamoxifen treatment.

120

121 **Table 1.** Pharmacogenetic Correlations in Breast Cancer Treatment.

122

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . medRxiv preprint doi: [https://doi.org/10.1101/2023.11.28.23299155;](https://doi.org/10.1101/2023.11.28.23299155) this version posted December 1, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

 123

124 **DISCUSSION**

125

In examining the role of pharmacogenetics in breast cancer treatment, it's essential to recognize the limitations of current genetic panels: they often lag behind the latest research developments and tend to focus on a narrow range of genetic variations. This approach can overlook critical genetic variations that have emerged as statistically significant, while still including those that have become less relevant [1]. Additionally, these studies predominantly target individuals of European descent, resulting in a lack of genetic diversity. This narrow focus can lead to research outcomes that do not adequately represent the entire global population, potentially limiting their applicability across various ethnic groups or individuals 134 with diverse genetic backgrounds [14].

135

Another significant hurdle in the clinical adoption of pharmacogenetics is the associated high cost. Equipping and maintaining laboratories with the latest technology and skilled personnel to perform and interpret genetic testing, or outsourcing these services, presents a substantial financial challenge, especially for healthcare facilities in developing countries [15].

140

Despite its vast potential, pharmacogenetics encounters substantial obstacles, including the need for frequent updates to genetic panels to encompass a wider array of genes and the challenge of managing the high costs associated with this advanced technology and specialized training. Addressing these challenges is imperative for optimizing the use of personalized medicine in breast cancer treatment, ensuring it benefits patients from all ethnic and socioeconomic backgrounds.

147

148 **CONCLUSION**

149

150 Pharmacogenomics is applied to personalize first-line breast cancer treatments through the 151 identification of genetic variations that impact the efficacy and side effects of drugs like 152 Letrozole, Anastrozole, and Tamoxifen. This approach involves analyzing specific

genotypes, such as CYP19A1, CYP2A6, ESR1, ESR2, and UGT1A4 rs3732218, to understand their influence on drug metabolism and patient response. This methodology enables more accurate dose adjustments and treatment plans tailored to individual genetic profiles, thereby enhancing treatment effectiveness and reducing the risk of adverse effects. The study highlights the critical role of pharmacogenetics in advancing personalized medicine in breast cancer treatment, emphasizing the need for further research to explore the impact of various genetic variations on drug response.

REFERENCES

-
- 1. Tan, S.-H., Lee, S.-C., Goh, B.-C., & Wong, J. (2008). Pharmacogenetics in Breast Cancer Therapy. Clinical Cancer Research, 14(24), 8027-8041.
-
- 2. Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., &
- Klein, T. E. (2021). An evidence-based framework for evaluating pharmacogenomics
- knowledge for personalized medicine. Clinical Pharmacology & Therapeutics. [Online ahead of print].
-
- 3. Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F.,
- Altman, R. B., & Klein, T. E. (2012). Pharmacogenomics knowledge for personalized
- medicine. Clinical Pharmacology & Therapeutics, 92(4), 414-417.
-
- 4. Nagasubramanian, R., Innocenti, F., & Ratain, M. J. (2003). Pharmacogenetics in cancer
- treatment. Annual Review of Medicine, 54, 437-452. doi:
- 10.1146/annurev.med.54.101601.152352.
-
- 5. Wong, Z.-W., & Ellis, M. J. (2004). First-line endocrine treatment of breast cancer:
- aromatase inhibitor or antioestrogen? British Journal of Cancer, 90, 20-25.
-
- 6. Liewei, W., Ellsworth, K. A., Moon, I., Pelleymounter, L., et al. (2010). Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Research.
-
- 7. Desta, Z., et al. (2011). Plasma letrozole concentrations in postmenopausal women with
- breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
- Clinical Pharmacology and Therapeutics.
-
- 8. Oesterreich, S., et al. (2015). Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast Cancer Research and Treatment.
-
- 9. Koroth, E. V., et al. (2013). Potential role of UGT1A4 promoter SNPs in anastrozole
- pharmacogenomics. Drug Metabolism and Disposition: The Biological Fate of Chemicals.
-

- 10. Goetz, M. P., Sangkuhl, K., Guchelaar, H.-J., et al. (2018). Clinical Pharmacogenetics
- Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clinical 199 Pharmacology & Therapeutics.
-
- 11. Insee, S., et al. (2016). ABCB1 and ABCC2 and the risk of distant metastasis in Thai
- breast cancer patients treated with tamoxifen. OncoTargets and Therapy.
-
- 12. Ntukidem, N. I., et al. (2008). Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clinical Pharmacology and Therapeutics.
-
- 13. Ingle, J. N., et al. (2013). Selective estrogen receptor modulators and pharmacogenomic
- variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer
- prevention. Cancer Discovery.
-
- 14. Patel, J. N. (2015). Cancer pharmacogenomics: implications on ethnic diversity and drug
- response. Pharmacogenetics and Genomics, 25(5), 223-230.
-
- 15. Wong, W. B., Carlson, J. J., Thariani, R., & Veenstra, D. L. (2010). Cost effectiveness of
- pharmacogenomics: a critical and systematic review. [Journal name not provided], 28(11),
- 1001-1013.